Menu
Back to Archived Journals » Gastrointestinal Cancer: Targets and Therapy » Volume 1
Role of sunitinib for the management of pancreatic neuroendocrine tumors
Authors Reidy-Lagunes D, Wyluda E
Published 15 August 2011 Volume 2011:1 Pages 53—57
DOI https://doi.org/10.2147/GICTT.S18231
Review by Single anonymous peer review
Peer reviewer comments 4
Diane L Reidy-Lagunes1,2, Ed EW Wyluda1
1Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Weill College of Medicine, Cornell University, New York, NY, USA
Abstract: Well differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor now multinationally approved for progressive pancreatic NETs but not for carcinoid tumors. The recommended dose as per the Phase III trial is 37.5 mg daily. In a Phase III trial, sunitinib demonstrated superior efficacy to best supportive care. As a result, sunitinib is now considered a standard treatment option for patients with progressive pancreatic NETs. Sunitinib has a distinct profile of adverse events, which will be discussed in this review. In addition, an in-depth critical review of sunitinib, with particular focus on the Phase III data, is discussed.
Keywords: pNET, carcinoid tumor, pancreatic tumor
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.